Skip to main content
Erschienen in:

01.07.2007 | Leitthema

Depressionen bei Patienten mit Tumorerkrankungen

verfasst von: PD Dr. M. Schäfer

Erschienen in: Die Onkologie | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Depressionen sind ein häufiges Problem bei onkologischen Patienten. Die Prävalenz wird mit 5–46% angegeben. Depressionen entstehen bei onkologischen Patienten oft als akute Überlastungsreaktion oder Anpassungsstörung. Im Rahmen manifester Depressionen werden eine Überaktivierung der Stress-Hormon-Achse sowie Neurotransmitter- und immunologische Veränderungen als neurobiologische Ursachen diskutiert. An sekundäre organische Depressionen aufgrund von ZNS-Beteiligungen sowie medikamenteninduzierte Depressionen ist zu denken. Aufgrund von Hinweisen, dass depressive Syndrome sowohl Therapieerfolg als auch die Überlebensrate negativ beeinflussen können, erscheint die konsequente Erfassung und Behandlung von Depressionen zunehmend wichtig. Kurzscreeninginstrumente erlauben mittlerweile eine schnelle und umfangreiche Erfassung depressiver Syndrome in der Onkologie und Palliativmedizin. Trotzdem erhalten bisher nur maximal 40% aller palliativmedizinischen Patienten eine ausreichende antidepressive Therapie. Für eine antidepressive Behandlung konnten unabhängig vom Krankheitsstadium positive Effekte gezeigt werden. Allerdings werden mehr prospektive, kontrollierte Studien benötigt. Derzeit sollte die Therapie depressiver Syndrome unter Berücksichtigung spezifischer Besonderheiten bei onkologischen Patienten in Anlehnung an gängige psychiatrische Leitlinien zur Depressionsbehandlung erfolgen.
Literatur
1.
Zurück zum Zitat Egede LE, Nietert PJ, Zheng D (2005) Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 28(6): 1339–1345PubMedCrossRef Egede LE, Nietert PJ, Zheng D (2005) Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 28(6): 1339–1345PubMedCrossRef
2.
Zurück zum Zitat Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML (2000) Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 160(9): 1261–1268PubMedCrossRef Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML (2000) Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 160(9): 1261–1268PubMedCrossRef
3.
Zurück zum Zitat Onitilo AA, Nietert PJ, Egede LE (2006) Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 28(5): 396–402PubMedCrossRef Onitilo AA, Nietert PJ, Egede LE (2006) Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 28(5): 396–402PubMedCrossRef
4.
Zurück zum Zitat Loberiza FR jr, Rizzo JD, Bredeson CN et al. (2002) Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 20(8): 2118–2126PubMedCrossRef Loberiza FR jr, Rizzo JD, Bredeson CN et al. (2002) Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 20(8): 2118–2126PubMedCrossRef
5.
Zurück zum Zitat Davidson KW, Kupfer DJ, Bigger JT et al. (2006) Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 68(5): 645–650PubMedCrossRef Davidson KW, Kupfer DJ, Bigger JT et al. (2006) Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 68(5): 645–650PubMedCrossRef
6.
7.
Zurück zum Zitat Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMed Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMed
8.
Zurück zum Zitat Beck AT, Ward CH, Mendelson M et al. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571PubMed Beck AT, Ward CH, Mendelson M et al. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571PubMed
9.
Zurück zum Zitat Zung WW (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63–70PubMed Zung WW (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63–70PubMed
10.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6): 361–370PubMed Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6): 361–370PubMed
11.
Zurück zum Zitat Roberts RE (1980) Reliability of the CES-D Scale in different ethnic contexts. Psychiatry Res 2(2): 125–134PubMedCrossRef Roberts RE (1980) Reliability of the CES-D Scale in different ethnic contexts. Psychiatry Res 2(2): 125–134PubMedCrossRef
12.
Zurück zum Zitat Massie MJ, Holland JC (1990) Depression and the cancer patient. J Clin Psychiatry 51 Suppl: 12–17 Massie MJ, Holland JC (1990) Depression and the cancer patient. J Clin Psychiatry 51 Suppl: 12–17
13.
Zurück zum Zitat Hotopf M, Chidgey J, Addington-Hall J, Ly KL (2002) Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 16(2): 81–97PubMedCrossRef Hotopf M, Chidgey J, Addington-Hall J, Ly KL (2002) Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 16(2): 81–97PubMedCrossRef
14.
Zurück zum Zitat Ly KL, Chidgey J, Addington-Hall J, Hotopf M (2002) Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 16(4): 279–284PubMedCrossRef Ly KL, Chidgey J, Addington-Hall J, Hotopf M (2002) Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 16(4): 279–284PubMedCrossRef
15.
Zurück zum Zitat Ita D, Keorney M, O’Slorain L (2003) Psychiatric disorder in a palliative care unit. Palliat Med 17(2): 212–218PubMedCrossRef Ita D, Keorney M, O’Slorain L (2003) Psychiatric disorder in a palliative care unit. Palliat Med 17(2): 212–218PubMedCrossRef
16.
Zurück zum Zitat Derogatis LR, Morrow GR, Fetting J et al. (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249(6): 751–757PubMedCrossRef Derogatis LR, Morrow GR, Fetting J et al. (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249(6): 751–757PubMedCrossRef
17.
Zurück zum Zitat Duffy SA, Ronis DL, Valenstein M et al. (2007) Depressive symptoms, smoking, drinking, and quality of life among head and neck cancer patients. Psychosomatics 48(2): 142–148PubMedCrossRef Duffy SA, Ronis DL, Valenstein M et al. (2007) Depressive symptoms, smoking, drinking, and quality of life among head and neck cancer patients. Psychosomatics 48(2): 142–148PubMedCrossRef
18.
Zurück zum Zitat Wilson KG, Chochinov HM, Skirko MG et al. (2007) Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 33(2): 118–129PubMedCrossRef Wilson KG, Chochinov HM, Skirko MG et al. (2007) Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 33(2): 118–129PubMedCrossRef
19.
Zurück zum Zitat Sellick SM, Edwardson AD (2006) Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psychooncology DOI 10.1002/pon.1085 Sellick SM, Edwardson AD (2006) Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psychooncology DOI 10.1002/pon.1085
20.
Zurück zum Zitat Goldstein D, Bennett B, Friedlander M et al. (2006) Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer 6: 240PubMedCrossRef Goldstein D, Bennett B, Friedlander M et al. (2006) Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer 6: 240PubMedCrossRef
21.
Zurück zum Zitat Pasquini M, Biondi M, Costantini A et al. (2006) Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety 23(7): 441–448PubMedCrossRef Pasquini M, Biondi M, Costantini A et al. (2006) Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety 23(7): 441–448PubMedCrossRef
22.
Zurück zum Zitat Voltz R, Borasio GD (2001) Neuropsychiatric symptoms in palliative care. Schmerz 15(5): 339–343PubMedCrossRef Voltz R, Borasio GD (2001) Neuropsychiatric symptoms in palliative care. Schmerz 15(5): 339–343PubMedCrossRef
23.
Zurück zum Zitat Inagaki M, Matsuoka Y, Sugahara Y et al. (2004) Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors. Am J Psychiatry 161(12): 2263–227PubMedCrossRef Inagaki M, Matsuoka Y, Sugahara Y et al. (2004) Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors. Am J Psychiatry 161(12): 2263–227PubMedCrossRef
24.
Zurück zum Zitat Kissane DW, McKenzie M, McKenzie DP et al. (2003) Psychosocial morbidity associated with patterns of family functioning in palliative care: baseline data from the Family Focused Grief Therapy controlled trial. Palliat Med 17(6): 527–537PubMedCrossRef Kissane DW, McKenzie M, McKenzie DP et al. (2003) Psychosocial morbidity associated with patterns of family functioning in palliative care: baseline data from the Family Focused Grief Therapy controlled trial. Palliat Med 17(6): 527–537PubMedCrossRef
25.
Zurück zum Zitat Butow PN, Coates AS, Dunn SM (1999) Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 17(7): 2256–2263PubMed Butow PN, Coates AS, Dunn SM (1999) Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 17(7): 2256–2263PubMed
26.
Zurück zum Zitat Stoppel C, Bielau H, Bogerts B, Northoff G (2006) Neurobiological basis of depressive disorders. Fortschr Neurol Psychiatr 74(12): 696–705PubMedCrossRef Stoppel C, Bielau H, Bogerts B, Northoff G (2006) Neurobiological basis of depressive disorders. Fortschr Neurol Psychiatr 74(12): 696–705PubMedCrossRef
27.
Zurück zum Zitat Ronson A (2004) Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks. Curr Opin Oncol 16(4): 318–323PubMedCrossRef Ronson A (2004) Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks. Curr Opin Oncol 16(4): 318–323PubMedCrossRef
28.
Zurück zum Zitat Caspi A, Sugden K, Moffitt TE et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631): 386–389PubMedCrossRef Caspi A, Sugden K, Moffitt TE et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631): 386–389PubMedCrossRef
29.
Zurück zum Zitat Patten SB, Barbui C (2004) Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom (73): 207–215 Patten SB, Barbui C (2004) Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom (73): 207–215
30.
Zurück zum Zitat Schaefer M, Schmidt F, Horn M et al. (2004) Depression during treatment with interferon alpha. Psychosomatics 45(2): 176PubMedCrossRef Schaefer M, Schmidt F, Horn M et al. (2004) Depression during treatment with interferon alpha. Psychosomatics 45(2): 176PubMedCrossRef
31.
Zurück zum Zitat Schaefer M, Engelbrecht MA, Gut O et al. (2002) Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26(4): 731–746PubMedCrossRef Schaefer M, Engelbrecht MA, Gut O et al. (2002) Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26(4): 731–746PubMedCrossRef
32.
Zurück zum Zitat Schaefer M, Schwaiger M, Pich M et al. (2003) Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 (Suppl 3): S203–S206PubMedCrossRef Schaefer M, Schwaiger M, Pich M et al. (2003) Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 (Suppl 3): S203–S206PubMedCrossRef
33.
Zurück zum Zitat Schafer M, Schwaiger M (2003) Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects. Fortschr Neurol Psychiatr 71(9): 469–476PubMedCrossRef Schafer M, Schwaiger M (2003) Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects. Fortschr Neurol Psychiatr 71(9): 469–476PubMedCrossRef
34.
Zurück zum Zitat Schaefer M, Horn M, Schmidt F et al. (2004) Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 18(6): 555–562PubMedCrossRef Schaefer M, Horn M, Schmidt F et al. (2004) Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 18(6): 555–562PubMedCrossRef
35.
Zurück zum Zitat Maes M (1999) Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461: 25–46PubMed Maes M (1999) Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461: 25–46PubMed
36.
Zurück zum Zitat Inagaki M, Yoshikawa E, Kobayakawa M et al. (2007) Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis. J Affect Disord 99(1–3): 231–236 Inagaki M, Yoshikawa E, Kobayakawa M et al. (2007) Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis. J Affect Disord 99(1–3): 231–236
37.
Zurück zum Zitat Yoshikawa E, Matsuoka Y, Yamasue H et al. (2006) Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. Biol Psychiatry 59(8): 707–712PubMedCrossRef Yoshikawa E, Matsuoka Y, Yamasue H et al. (2006) Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. Biol Psychiatry 59(8): 707–712PubMedCrossRef
38.
Zurück zum Zitat Rodin G, Lloyd N, Katz M et al. (2007) The treatment of depression in cancer patients: a systematic review. Support Care Cancer 15(2): 123–136PubMedCrossRef Rodin G, Lloyd N, Katz M et al. (2007) The treatment of depression in cancer patients: a systematic review. Support Care Cancer 15(2): 123–136PubMedCrossRef
39.
Zurück zum Zitat Fisch MJ, Loehrer PJ, Kristeller J et al. (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 21(10): 1937–1943PubMedCrossRef Fisch MJ, Loehrer PJ, Kristeller J et al. (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 21(10): 1937–1943PubMedCrossRef
40.
Zurück zum Zitat Manne SL, Andrykowski MA (2006) Are psychological interventions effective and accepted by cancer patients? II. Using empirically supported therapy guidelines to decide. Ann Behav Med 32(2): 98–103PubMedCrossRef Manne SL, Andrykowski MA (2006) Are psychological interventions effective and accepted by cancer patients? II. Using empirically supported therapy guidelines to decide. Ann Behav Med 32(2): 98–103PubMedCrossRef
41.
Zurück zum Zitat Pai AL, Drotar D, Zebracki K et al. (2006) A meta-analysis of the effects of psychological interventions in pediatric oncology on outcomes of psychological distress and adjustment. J Pediatr Psychol 31(9): 978–988PubMedCrossRef Pai AL, Drotar D, Zebracki K et al. (2006) A meta-analysis of the effects of psychological interventions in pediatric oncology on outcomes of psychological distress and adjustment. J Pediatr Psychol 31(9): 978–988PubMedCrossRef
42.
Zurück zum Zitat Kugaya A, Akechi T, Nakano T et al. (1999) Successful antidepressant treatment for five terminally ill cancer patients with major depression, suicidal ideation and a desire for death. Support Care Cancer 7(6): 432–436PubMedCrossRef Kugaya A, Akechi T, Nakano T et al. (1999) Successful antidepressant treatment for five terminally ill cancer patients with major depression, suicidal ideation and a desire for death. Support Care Cancer 7(6): 432–436PubMedCrossRef
43.
Zurück zum Zitat Baghai TC, Volz HP, Moller HJ (2006) Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7(4): 198–222PubMedCrossRef Baghai TC, Volz HP, Moller HJ (2006) Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7(4): 198–222PubMedCrossRef
44.
Zurück zum Zitat Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3(1): 5–43PubMed Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3(1): 5–43PubMed
45.
Zurück zum Zitat Ridwelski K, Meyer F (2001) Current options for palliative treatment in patients with pancreatic cancer. Dig Dis 19(1): 63–75PubMedCrossRef Ridwelski K, Meyer F (2001) Current options for palliative treatment in patients with pancreatic cancer. Dig Dis 19(1): 63–75PubMedCrossRef
46.
Zurück zum Zitat Miller K, Massie MJ (2006) Depression and anxiety. Cancer J 12(5): 388–397PubMed Miller K, Massie MJ (2006) Depression and anxiety. Cancer J 12(5): 388–397PubMed
47.
Zurück zum Zitat Herrmann-Lingen C (2003) The importance of depressive disorders in somatic medicine. Z Psychosom Med Psychother 49(4): 391–407PubMed Herrmann-Lingen C (2003) The importance of depressive disorders in somatic medicine. Z Psychosom Med Psychother 49(4): 391–407PubMed
48.
Zurück zum Zitat Holland JC (2003) American Cancer Society Award lecture. Psychological care of patients: psycho-oncology’s contribution. J Clin Oncol 21(23 Suppl): 253s-265sPubMedCrossRef Holland JC (2003) American Cancer Society Award lecture. Psychological care of patients: psycho-oncology’s contribution. J Clin Oncol 21(23 Suppl): 253s-265sPubMedCrossRef
49.
Zurück zum Zitat Boesen EH, Ross L, Frederiksen K et al. (2005) Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 23(6): 1270–1277PubMedCrossRef Boesen EH, Ross L, Frederiksen K et al. (2005) Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 23(6): 1270–1277PubMedCrossRef
50.
Zurück zum Zitat Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3(2): 69–86PubMedCrossRef Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3(2): 69–86PubMedCrossRef
Metadaten
Titel
Depressionen bei Patienten mit Tumorerkrankungen
verfasst von
PD Dr. M. Schäfer
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 7/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-007-1213-0

Weitere Artikel der Ausgabe 7/2007

Die Onkologie  7/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Carcinoma of unknown primary (CUP-Syndrom)

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.